Automatic classification of lymphoma lesions in FDG-PET-Differentiation between tumor and non-tumor uptake.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
01
2022
accepted:
05
04
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
21
4
2022
Statut:
epublish
Résumé
The automatic classification of lymphoma lesions in PET is a main topic of ongoing research. An automatic algorithm would enable the swift evaluation of PET parameters, like texture and heterogeneity markers, concerning their prognostic value for patients outcome in large datasets. Moreover, the determination of the metabolic tumor volume would be facilitated. The aim of our study was the development and evaluation of an automatic algorithm for segmentation and classification of lymphoma lesions in PET. Pre-treatment PET scans from 60 Hodgkin lymphoma patients from the EuroNet-PHL-C1 trial were evaluated. A watershed algorithm was used for segmentation. For standardization of the scan length, an automatic cropping algorithm was developed. All segmented volumes were manually classified into one of 14 categories. The random forest method and a nested cross-validation was used for automatic classification and evaluation. Overall, 853 volumes were segmented and classified. 203/246 tumor lesions and 554/607 non-tumor volumes were classified correctly by the automatic algorithm, corresponding to a sensitivity, a specificity, a positive and a negative predictive value of 83%, 91%, 79% and 93%. In 44/60 (73%) patients, all tumor lesions were correctly classified. In ten out of the 16 patients with misclassified tumor lesions, only one false-negative tumor lesion occurred. The automatic classification of focal gastrointestinal uptake, brown fat tissue and composed volumes consisting of more than one tissue was challenging. Our algorithm, trained on a small number of patients and on PET information only, showed a good performance and is suitable for automatic lymphoma classification.
Identifiants
pubmed: 35436321
doi: 10.1371/journal.pone.0267275
pii: PONE-D-22-03090
pmc: PMC9015138
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0267275Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3198-3220
pubmed: 33604689
Leuk Lymphoma. 2017 Oct;58(10):2298-2303
pubmed: 28264597
Leuk Lymphoma. 2009 Aug;50(8):1257-60
pubmed: 19544140
Clin Nucl Med. 2019 Oct;44(10):e559-e565
pubmed: 31306204
BMJ Open. 2021 Mar 29;11(3):e041252
pubmed: 33782017
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):501-512
pubmed: 30763664
Klin Padiatr. 2013 Nov;225(6):357-61
pubmed: 24166093
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1362-1370
pubmed: 33097974
J Clin Oncol. 2015 Sep 20;33(27):2975-85
pubmed: 26304892
J Nucl Med. 2021 Jan;62(1):30-36
pubmed: 32532925
J Clin Oncol. 2011 May 10;29(14):1844-54
pubmed: 21482982
Front Med (Lausanne). 2021 Feb 26;8:628179
pubmed: 33718406
Sci Rep. 2018 Mar 02;8(1):3913
pubmed: 29500442
Radiology. 2020 Feb;294(2):445-452
pubmed: 31821122
Methods. 2021 Apr;188:105-111
pubmed: 32634555
J Clin Oncol. 2018 Jul 10;36(20):2024-2034
pubmed: 29750632
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
J Nucl Med. 2021 Mar;62(3):332-337
pubmed: 32680929
EJNMMI Res. 2021 Jan 6;11(1):4
pubmed: 33409747
Mol Imaging Biol. 2007 Mar-Apr;9(2):83-90
pubmed: 17225983
Lancet. 2012 Sep 1;380(9844):848-57
pubmed: 22835603
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):97-110
pubmed: 28411336
Acta Oncol. 2011 Jun;50(5):670-7
pubmed: 21247262
Lancet. 2012 Sep 1;380(9844):836-47
pubmed: 22835602